Filing identity and period
Important metadata mismatch: The supplied filing is Kintara Therapeutics, Inc.’s Form 10-K for the fiscal year ended June 30, 2020, filed September 18, 2020. It is not a Tuhura Biosciences filing and does not report 2019 Q4. Kintara was formerly DelMar Pharmaceuticals; it acquired Adgero and changed its name in August 2020, after fiscal year-end.
Business context
Kintara is a clinical-stage cancer therapeutics company with no product revenue to date. Its lead candidates are VAL-083, being developed principally for glioblastoma (GBM), and REM-001, a photodynamic therapy candidate for cutaneous metastatic breast cancer (CMBC). The August 2020 Adgero merger added REM-001 to the company; the merger was a subsequent event, not part of the June 30, 2020 year-end balance sheet.
Financial results and liquidity
| Metric (US$ unless stated) | FY ended June 30, 2020 | FY ended June 30, 2019 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $3.63 million | $3.66 million |
| General and administrative expense | $4.51 million | $4.74 million |
| Merger costs | $1.05 million | None |
| Net loss | $9.13 million | $8.05 million |
| Net loss per share | $0.87 | $3.16 |
| Cash used in operations | $7.93 million | $6.33 million |
| Cash and cash equivalents at year-end | $2.39 million | $3.72 million |
| Working capital | $0.18 million | $1.96 million |
| Total assets / total liabilities | $2.94 million / $2.67 million | $4.04 million / $2.07 million |
| Stockholders’ equity | $0.26 million | $1.97 million |
There are no meaningful revenue or profit margins to assess because the company had no revenue and reported a loss. FY2020 net loss increased by about $1.08 million; merger costs were a major new expense, while R&D and G&A expenses declined modestly. Cash used in operations rose about 25%. Fiscal-year financing activities provided $6.60 million, mainly from an August 2019 offering, but cash still declined by $1.33 million over the year. No cash-flow guidance or operating profitability target is provided.
Material developments, outlook and risks
- Post-year-end financing and merger: In three closings after June 30, Kintara raised approximately $25 million gross and $21.7 million net through Series C preferred stock alongside the Adgero merger. The preferred stock is convertible into approximately 21.52 million common shares and carries future share dividends of 10% to 25% at specified anniversaries. These terms create substantial potential dilution and preferred-stock seniority. Management estimated the cash available, including these proceeds, would fund planned operations into Q4 2021; the filing also says it expected funding beyond the next year from issuance of the financial statements. This is management’s estimate, not a guarantee.
- Additional loan: Kintara received $500,000 after year-end from the National Brain Tumor Society and National Foundation for Cancer Research. The loan bears 6% interest, is secured, and matures June 19, 2021; 125,000 warrants were issued in connection with it.
- VAL-083 clinical data and plans: Interim Phase 2 results disclosed in June 2020 included median progression-free survival of 8.7 months in the newly diagnosed study, compared with a cited historical 6.9 months for temozolomide in unmethylated GBM; this was not a head-to-head comparison. In recurrent GBM, median overall survival was 8.5 months for the 37 patients initially receiving the intended dose and 7.1 months for the 72-patient group. These are interim, company-reported findings and require confirmation in further trials. Planned milestones included first enrollment in the GBM AGILE study and newly diagnosed study results in Q4 2020; recurrent-study results in Q1 2021; and adjuvant-study results in Q2 2021.
- REM-001 development: Management planned a CMBC lead-in study, with first enrollment targeted for Q2 2021 and topline results for Q4 2021. Its efficacy case relies partly on analyses of Miravant trials conducted roughly two decades earlier; Kintara acknowledges the FDA may not accept the historical data as adequate support. At the filing date, manufacturing and device arrangements for the planned studies were still being advanced. FDA approval, orphan designation for CMBC and exclusivity were not assured.
- Funding and going concern: Before the post-year-end financing, the company had an accumulated deficit of $69.72 million and FY2020 operating cash outflow of $7.93 million. Management stated the financing alleviated substantial doubt about going concern, but further capital will be needed and may dilute shareholders or constrain development.
- Other material risks: COVID-19 could disrupt trial enrollment, treatment, data collection, manufacturing and access to capital. The merger carries integration risks. The company reported ineffective disclosure controls and a material weakness in internal control over financial reporting, citing inadequate segregation of duties; remediation was underway. Clinical efficacy, safety, regulatory review, third-party manufacturing and competition remain significant uncertainties.
Key facts investors should verify
- Confirm the filing’s issuer and period: Kintara Therapeutics, fiscal year ended June 30, 2020—not Tuhura Biosciences or 2019 Q4.
- Review the Series C preferred-stock conversion, share-dividend, liquidation and warrant terms, and assess fully diluted share count and potential dilution.
- Check actual cash burn and financing needs against management’s funding runway estimate, including the $500,000 loan and its repayment date.
- Track the status, enrollment, complete results and safety findings of VAL-083 studies; distinguish interim results from controlled, confirmatory evidence.
- Verify REM-001 study readiness, FDA feedback, manufacturing and device supply, and whether the FDA accepts the historical clinical data.
- Monitor remediation of the disclosed internal-control material weakness and any subsequent changes in reporting controls.